Bromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population

Simple item page
dc.contributor.authorArieh R. Mercado-Sesma
dc.contributor.authorClaudia Palacio-Pastrana
dc.contributor.authorLourdes Ortega
dc.contributor.authorFrancisco Bustos
dc.contributor.authorEduardo Chávez
dc.contributor.authorAldo Oregon
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T15:09:48Z
dc.date.available2026-03-22T15:09:48Z
dc.date.issued2016
dc.descriptionCitaciones: 5
dc.description.abstractBromfenac 0.09% ophthalmic solution showed similar clinical efficacy to reduce the presentation of CME after phacoemulsification compared to nepafenac 0.01%.
dc.identifier.doi10.2147/opth.s93530
dc.identifier.urihttps://doi.org/10.2147/opth.s93530
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/50751
dc.language.isoen
dc.publisherDove Medical Press
dc.relation.ispartofClinical ophthalmology
dc.sourceUniversidad Nuestra Señora de La Paz
dc.subjectMedicine
dc.subjectChemosis
dc.subjectOphthalmology
dc.subjectMacular edema
dc.subjectIntraocular pressure
dc.subjectPhacoemulsification
dc.subjectEdema
dc.subjectPlacebo
dc.subjectUveitis
dc.subjectAnesthesia
dc.titleBromfenac 0.09% bioavailability in aqueous humor, prophylactic effect on cystoid macular edema, and clinical signs of ocular inflammation after phacoemulsification in a Mexican population
dc.typearticle

Files

Collections

Artículo Científico Publicado